What's new?

European venture capital firm has raised €1 billion in the last 12 months across its expanding life science investment platform PARIS, France – October 19,¬ 2021 - Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the close of its latest earl...

Funding will support continued development of CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase product candidate, for the treatment of hypertension, primary aldosteronism and chronic kidney disease CINCINNATI, Oct. 12, 2021 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) today a...

- Financing round with top-tier life science venture capitalists, led by Athos Service and MIG Capital, joined by existing shareholders - The new funds will be used to advance iOmx' lead programs IMT-07 and IMT-18, both addressing novel immune checkpoint targets in oncology  

€66.5 million raised Market capitalisation of €206 million Greentech and French Tech 120 company Alumni of TechShare, Euronext’s pre-IPO programme  

Paris, France, August 31, 2021 - TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced it has closed a Series C round of financing, raising €50 million from new and existing international investors. Cathay Health, affiliated to global investment ...

Capital raise enables Sofinnova MD Start’s pioneering team to further support clinicians in transforming innovative ideas into medical realities Paris – July 13, 2021 - Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the final close of its ...

• Financing co-led by Novo Holdings, Sofinnova Partners, Droia Ventures and LSP Dementia Fund, with participation from Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures and VIB • Developing small molecules to repair neuronal dysfunction and resolve neuroinflammation • Innovative drug discov...

- Financing will be used to further develop proprietary discovery platform and progress pipeline targeting disease control and weed suppression - Company well positioned to enter and transform the EUR 47 billion-plus market for pesticides, initially targeting $28 billion herbicides and fungicides markets in America...

Ghent, BELGIUM – 01 July 2021 – Biotalys NV (“Biotalys” or the “Company”) an Agricultural Technology (AgTech) company focused on addressing food protection challenges with protein-based biocontrol solutions for a more sustainable and safer food supply, today announces the results of its initial public offering of n...

Key investments made through the Sofinnova Telethon Fund underscore the venture capital firm’s commitment to fostering a thriving Italian biotech ecosystem AAVantgarde Bio, Alia Therapeutics, and Borea Therapeutics are developing promising new therapies for rare, genetic disorders Milan, Italy – June 30, 2021 - Sof...